

# Blood Count Monitoring Post-Autologous SCT

## Introduction and Who this Standard Operating Procedure applies to

This CYPICS network standard operating procedure (SOP) has been developed by clinicians from Nottingham Children's Oncology Unit with consultation across the network including from the Leicester Royal Infirmary and has been ratified by the Leicester Children's Hospital guideline process.

This SOP applies to all children and young people under the age of 19 years who are receiving chemotherapy for malignant disease

UHL local Paediatric Oncology specialists are:

Emma Ross; Consultant Paediatric Oncologist

Ghazala Javid; Paediatric Oncology Pharmacist, Leicester Royal Infirmary

Dani Jones; CYPICS Clinical Educator

## Blood Count Monitoring Post-Autologous SCT

Title of Guideline		Guideline for monitoring blood counts following an autologous stem cell transplant
Contact Name and Job Title (author)		Dr Sophie Wilne, Consultant Oncologist Katie Manning, Quality Manager
Directorate & Speciality		Directorate: Family Health – Children Speciality: Paediatric Oncology
Date of submission of this version		21.09.2020
Date when guideline to be reviewed		21.09.2022
Guideline Number		ASCT/C/017
Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis)		This guideline applies to children and young people post-autologous stem cell transplant (SCT) prior to engraftment.
Abstract		This guideline outlines the frequency of blood count monitoring for children and young people post-autologous SCT prior to engraftment.
Key Words		Paediatrics. Children. Young People. Cancer. Autologous stem cell transplant. Full blood count. Neutrophil. Platelets. Blood count. Engraftment.
Statement of the evidence base of the guideline – has the guideline been peer reviewed by colleagues?		
1a	meta analysis of randomised controlled trials	
1b	At least one randomised controlled trial	
2a	at least one well-designed controlled study without randomisation	
2b	at least one other type of well-designed quasi-experimental study	
3	well –designed non-experimental descriptive studies (ie comparative / correlation and case studies)	
4	expert committee reports or opinions and / or clinical experiences of respected authorities	
5	recommended best practise based on the clinical experience of the guideline developer	X
Consultation Process		Paediatric Consultant Oncologists. Margaret Parr, Lead Nurse, CYPICS. Dani Jones, CYPICS Clinical Educator. Joanne Smallman, Ward Manager, E39.
Target audience		Clinical teams caring for children and young people post-autologous stem cell transplant.
<b>This guideline has been registered with the trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt contact a senior colleague or expert. Caution is advised when using guidelines after the review date.</b>		

Uncontrolled copy unless printed on green paper and signed by the Programme Director or Quality Manager

Authorised by	Name	Signature	Date
Programme Director	Dr Sophie Wilne	S Wilne	21.09.2020
Quality Manager	Katie Manning		

## Document Control

### Document Amendment Record

Version	Issue Date	Author
V1	September 2020	Dr Sophie Wilne, Katie Manning
V2		

### General Notes:

### Summary of changes for new version:

Uncontrolled copy unless printed on green paper and signed by the Programme Director or Quality Manager

## Contents

<u>1.</u>	<u>Introduction</u>	5
<u>2.</u>	<u>Purpose and Objectives</u>	5
<u>3.</u>	<u>Responsibilities</u>	5
<u>4.</u>	<u>Procedure</u>	6
<u>4.1</u>	<u>Engraftment</u>	6
<u>4.2</u>	<u>Blood count monitoring prior to engraftment</u>	6
<u>4.3</u>	<u>Blood count monitoring post-discharge (prior to platelet engraftment)</u>	6
<u>5.</u>	<u>Limitations</u>	6
<u>6.</u>	<u>References/ Further Information</u>	7

## 1. Introduction

- 1.1 Conditioning for Haemopoietic Stem Cell Transplantation (HSCT) leads to destruction of the cellular components of blood and bone marrow. Post HSCT there is reduced haemopoiesis until the new stem cells colonise the marrow. It is imperative that the clinical team monitor a patient's blood count frequently prior to engraftment to ensure that appropriate and timely supportive care is provided.
- 1.2 For the purposes of this guideline, blood count monitoring will specifically relate to full blood count (FBC).

## 2. Purpose and Objectives

- 2.1 The purpose of this guideline is to outline the required frequency of blood count monitoring in children and young people post-autologous stem cell transplant prior to engraftment.
- 2.2 Frequent monitoring of the child/young persons' FBC will assist the clinical team to provide timely supportive care including blood product transfusion to reduce the risk of bleeding or anaemia.
- 2.3 Blood count monitoring is essential to ensure that dates for engraftment are identified and can be reported to the European Group for Blood and Marrow Transplantation (EBMT) and NHS Blood Transfusion (NHSBT) as required.
- 2.4 Regular monitoring of blood counts will ensure that graft failure, although uncommon in children post-autologous SCT, is identified so that appropriate treatment can be initiated (see [ASCT/C/016](#) Diagnosis and Management of Graft Failure).

## 3. Responsibilities

- 3.1 The patient's consultant will be responsible for notifying the clinical team (nursing and medical) of any patient-specific variation in blood count monitoring from this guideline.
- 3.2 The medical team are responsible for analysis of the FBC and the initiation of any supportive therapy or graft failure management.
- 3.3 The patient's consultant is responsible for deciding the frequency of blood count monitoring following discharge home or to another care provider until platelet engraftment is evidenced.

Uncontrolled copy unless printed on green paper and signed by the Programme Director or Quality Manager

- 3.4** The discharging ward nurse and liaison nurses are responsible for communicating the frequency of blood count monitoring to the community teams or nursing team in another care provider following discharge. The medical team should include the frequency of blood count monitoring within the transfer letter if the child/young person is being transferred to another care provider.
- 3.5** The liaison nurses or E39 day care nursing team will check the results of blood counts obtained post-discharge and will escalate results as required to a member of the medical team.

## **4. Procedure**

### **4.1 Engraftment**

- 4.1.1** Neutrophil engraftment is defined as the 1<sup>st</sup> of 3 consecutive days with an actual neutrophil count (ANC) of  $\geq 0.5 \times 10^9/l$ . Platelet engraftment is defined as the 1<sup>st</sup> of 3 consecutive days the platelet count is  $\geq 20 \times 10^9/l$  including 7 consecutive days without platelet transfusion.

### **4.2 Blood count monitoring prior to engraftment**

- 4.2.1** FBC should be monitored at a minimum daily and more frequently if clinical condition indicates e.g. rapidly falling platelet count, active bleeding.
- 4.2.2** Each FBC result must be checked by a member of the medical team. Transfusion support should be provided as per [ASCT/C/ 018](#) Transfusion Support for children and young people with malignancy and bone marrow failure.

### **4.3 Blood count monitoring post-discharge (prior to platelet engraftment)**

- 4.3.1** FBC should be monitored at a minimum twice weekly until platelet engraftment.
- 4.3.2** More frequent FBC monitoring should be undertaken if the child/young person is requiring more frequent platelet transfusions. In this instance, the required frequency will be a consultant decision.
- 4.3.3** The FBC results must be checked on the day the sample has been obtained and recorded within the day care blood results folder.

## **5. Limitations**

- 5.1** Post discharge the child/young person may need their blood count checking more frequently in the event of becoming unwell or signs of bleeding.

## 6. References/ Further Information

ASCT/C/018 Transfusion Support for children and young people with malignancy and bone marrow failure

### UHL Education and Training

None

### Key Words

Children, CYPICS, Haemopoietic Stem Cell Transplant (HSCT), Haematology, Oncology  
Young People:

---

The Trust recognises the diversity of the local community it serves. Our aim therefore is to provide a safe environment free from discrimination and treat all individuals fairly with dignity and appropriately according to their needs. As part of its development, this policy and its impact on equality have been reviewed and no detriment was identified.

CONTACT AND REVIEW DETAILS	
<b>SOP Lead (Name and Title)</b> Emma Ross; Consultant Paediatric Oncologist	<b>Executive Lead</b> Chief Medical Officer
<b>Details of Changes made during review:</b> New SOP	

Uncontrolled copy unless printed on green paper and signed by the Programme Director or Quality Manager